- Torrent Pharmaceuticals reported a net income of 4.98 billion rupees for the fourth quarter, which is an 11% increase year-over-year but below the estimated 5.24 billion rupees.
- Revenue rose by 7.6% year-over-year to 29.6 billion rupees, slightly missing the estimate of 29.88 billion rupees.
- Domestic sales increased by 12% year-over-year to 15.5 billion rupees, surpassing the estimate of 15.46 billion rupees.
- US revenue showed a strong growth of 15% year-over-year, reaching 3.02 billion rupees, exceeding the estimate of 2.83 billion rupees.
- Revenue from Brazil decreased by 5.9% year-over-year to 3.5 billion rupees, falling short of the 3.52 billion rupees estimate.
- German revenue growth was modest at 2.1% year-over-year, resulting in 2.86 billion rupees, compared to the 3.01 billion rupees estimate.
- Total costs rose 4.7% year-over-year, amounting to 22.5 billion rupees.
- Research and development expenses increased 7.9% year-over-year to 1.50 billion rupees, slightly below the 1.51 billion rupees estimate.
- EBITDA rose by 9.2% year-over-year to 9.64 billion rupees, missing the 9.81 billion rupees estimate.
- The gross margin improved slightly to 75.3%, from 75% the previous year, meeting the estimate of 75.2%.
- A dividend of 6 rupees per share has been declared.
- The company is seeking enabling approval for an INR50 billion equity issue.
- The board has approved the appointment of Aman Mehta as Managing Director, effective August 1.
- The stock has 19 buy ratings, 9 hold ratings, and 5 sell ratings from analysts.
A look at Torrent Pharmaceuticals Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 4 | |
| Growth | 3 | |
| Resilience | 4 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on Smartkarma Smart Scores, Torrent Pharmaceuticals is positioned favorably for long-term growth and stability. With a solid Dividend score of 4 and high Resilience and Momentum scores of 4 each, the company shows promise in providing consistent returns to investors. Additionally, the Growth score of 3 indicates moderate potential for expansion in the pharmaceutical industry. Torrent Pharmaceuticals‘ focus on manufacturing bulk drugs and a range of pharmaceutical formulations, including cardio-vascular and psychotropic drugs, suggests a diverse product portfolio that may contribute to sustained performance.
Furthermore, Torrent Pharmaceuticals‘ presence in both regulated and less regulated international markets through its wholly owned subsidiaries enhances its global reach and market access. While the Value score of 2 implies some room for improvement in terms of valuation, the overall outlook for Torrent Pharmaceuticals appears promising, with its strong performance in dividends, resilience, and growth areas boding well for future prospects in the pharmaceutical sector.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
